Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
  • A61K51/04—Organic compounds
  • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/16—Purine radicals

Definitions

• the present invention relates to methods and compositions for carrying out pharmacological stress imaging with certain alkynyladenosine compounds.
• Pharmacologic stress is increasingly being employed as an alternative to exercise stress in patients undergoing nuclear or echocardiographic imaging for the detection of coronary artery disease. It is frequently induced with adenosine or dipyridamole in patients with suspected coronary artery disease prior to imaging with radiolabeled perfusion tracers such as 201 T1 or 99m Tc-sestamibi, or by echocardiography. In 1999, it is predicted that 1.7 million patients will be studied using pharmacologic stress imaging in the United States alone. The advantage of pharmacologic vasodilatation over exercise is that pharmacologic stress results in a repeatable level of coronary flow increase which is not dependent upon patient fitness and/or motivation.
• adenosine and dipyridamole stress perfusion imaging ranging between 85-90%.
• a major disadvantage of using adenosine or dipyridamole stress is that there is an unusually high incidence of adverse side effects with both of these vasodilators.
• 82% experienced adverse side effects (M. D. Cequiera et al., T Am. Coll. Cardiol.. 21, 384 (1994)).
• the desired coronary vasodilatation is mediated by the stimulation of the adenosine A 2A receptor by adenosine
• most of the side effects are caused by stimulation of the other three adenosine receptor subtypes: A,, A 2B , and A 3 .
• a pre-treatment strategy with an adenosine receptor antagonist may reduce some side effects and improve patient comfort and safety
• a simpler strategy would be to design a vasodilator that has little or no affinity for the adenosine A,, A 2B or A 3 receptor subtypes, but that selectively stimulates the A 2A receptors.
• a 2A adenosine receptors AR
• compounds with little or no selectivity for A 2A receptors were developed, such as adenosine itself or 5'-carboxamides of adenosine, such as 5'-N- ethylcarboxamidoadenosine (NECA) (B. N. Cronstein et al., J. Immunol., 1 5, 1366 (1985)).
• NECA 5'-N- ethylcarboxamidoadenosine
• 2-alkylamino substituents increased potency and selectivity, e.g., CV1808 and CGS21680 (M. F. Jarvis et al., J. Pharmacol. F.xp. Ther.. 25_L, 888 (1989)).
• 2-Alkoxy-substituted adenosine derivatives such as WRC-0090 are even more potent and selective as agonists at the coronary artery A 2A receptor (M. Ueeda et al., J. Med. Chem., 34, 1334 (1991)).
• Olsson et al. U.S. Pat. No. 5,140,015 disclose certain adenosine A 2 receptor agonists of formula:
• C(X)BR 2 can be CH 2 OH and R, can be alkyl- or alkoxyalkyl.
• the compounds are disclosed to be useful as vasodilators or an antihypertensives.
• Linden et al. (U.S. Pat. No. 5,877,180) is based on the discovery that certain inflammatory diseases, such as arthritis and asthma, may be effectively treated by the administration of compounds which are selective agonists of A 2A adenosine receptors, preferably in combination with a Type IV phosphodiesterase inhibitor.
• An embodiment of the Linden et al. invention provides a method for treating inflammatory diseases by administering an effective amount of an A 2A adenosine receptor of the following formula:
• Mohiuddin et al. U.S. Pat. No. 5,070,877 discloses the use of the relatively nonspecific adenosine analog, 2-chloroadenosine (Cl-Ado), as a pharmacological stressor.
• the Cl-Ado analog is actually a more potent activator of A, adenosine receptors than of A 2A adenosine receptors and, thus, is likely to cause side effects due to activation of A] receptors on cardiac muscle and other tissues causing effects such as "heart block.”
• G. Cristalli U.S. Pat. No. 5,593,975 discloses 2-arylethynyl, 2- cycloalkylethynyl or 2-hydroxyalkylethynyl derivatives, wherein the riboside residue is substituted by carboxy amino, or substituted carboxy amino (R 3 HNC(O)-).
• 2-Alkynylpurine derivatives have also been disclosed in Miyasaka et al. (U.S. Pat. No. 4,956,345), wherein the 2-alkynyl group is substituted with (C 3 -C 16 )alkyl.
• the '975 compounds are disclosed to be vasodilators and to inhibit platelet aggregation, and thus to be useful as anti- ischemic, anti-atherosclerosis and anti-hypertensive agents.
• Rib is ribosyl, R, can be H and R 2 can be cycloalkyl.
• the compounds are disclosed to be useful for treating hypertension, atherosclerosis and as vasodilators.
• the present invention comprises compounds and methods of their use for detecting the presence of, and assessing the severity of myocardial perfusion abnormalities, such as due to coronary artery stenosis in a mammal, such as a human or domestic animal.
• the compounds of the invention are used as pharmacological stress-inducing agents or stressors that are useful in pharmacological stress imaging for the detection and assessment of coronary artery stenosis due to coronary artery disease.
• the preferred compounds of the invention are potent and selective at A 2A adenosine receptors, but are also short- acting, so that they are rapidly cleared by the body following the imaging process.
• the present compounds comprise a novel class of 2-alkynyladenosine derivatives, substituted at the ethyne position by substituted cycloalkyl moieties.
• the riboside residue is substituted at the 5 '-position ("X") by an N- alkyl-(or N-cycloalkyl)aminocarbonyl moiety.
• the present invention provides a method for detecting the presence and severity of coronary artery stenosis in a mammal, such as a human subject, comprising (1) administering an amount of one or more compounds of the general formula (I):
• each R is individually hydrogen, C,-C 6 alkyl, C 3 -C 7 cycloalkyl, phenyl or phenyl(C,-C 3 )-alkyl;
• X is -CH 2 OH, -CO 2 R 2 , -OC(O)R 2 or C(O)NR 3 R 4 ;
• each of R 2 , R 3 and R 4 is individually H, C,_ 6 -alkyl; C,_ 6 -alkyl substituted with 1-3 C, .6 -alkoxy, C 3 _ 7 -cycloalkyl, C,_ 6 -alkylthio, halogen, hydroxy, amino, mono(C, .6 -alkyl)amino, d ⁇ C ⁇ -alky ⁇ amino, or C 6.10 -aryl, wherein aryl may be substituted with 1-3 halogen, C, .6 -alkyl, hydroxy, amino, mono(C, .6 -alkyl)amino, or di(C, .6 -alkyl)amino; C ⁇ -aryl; or C 6.
• 0 -aryl substituted with 1-3 halogen, hydroxy, amino, mono(C,. 6 -alkyl)amino, di(C, .6 - alkyl)amino, or C, .6 - alkyl;
• R 1 is (X-(Z)-) n [(C 3 -C 10 )cycloalkyl]-(Z')- wherein Z and Z' are individually (C,-C 6 )alkyl, optionally interrupted by 1-3 S or nonperoxide O, or is absent, and n is 1-3; or a pharmaceutically acceptable salt thereof, wherein the amount is effective to provide coronary vasodilation; and (2) performing a technique on said mammal to detect and/or determine the severity of said coronary artery stenosis.
• the invention provides a compound of formula I for use in medical diagnostic procedures, preferably for use in detecting the presence of, and assessing the severity of coronary artery stenosis, e.g., due to coronary artery disease in a human subject.
• the present invention provides the use of a compound of formula I for the manufacture of a pharmacologic vasodilator which can be used with perfusion imaging techniques for diagnosing and assessing the extent of coronary artery stenosis. While the stenosis can be due to coronary artery disease, i.e., atherosclerosis, it can also be due to angioplasty, stent placement or failure and the like.
• Preferred perfusion imaging techniques are planar or single photon emission computed tomography (SPECT), gamma camera scintigraphy, positron emission tomography (PET), nuclear magnetic resonance (NMR) imaging, perfusion contrast echocardiography, digital subtraction angiography (DSA) and ultrafast X-ray computed tomography (CINE CT).
• SPECT computed tomography
• PET positron emission tomography
• NMR nuclear magnetic resonance
• DSA digital subtraction angiography
• CINE CT ultrafast X-ray computed tomography
• the invention also provides a pharmaceutical composition
• a pharmaceutical composition comprising an effective amount of the compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable diluent or carrier.
• the composition is presented as a unit dosage form, and can be adapted for parenteral, e.g., intravenous infusion.
• Figure 1 Competitive binding assay showing the relative potency of three adenosine A 2A receptor agonists vs CGS-21680 in recombinant human adenosine receptors.
• Figure 2 Left circumflex (LCx) coronary flow response to varying doses of JMR-193 administered by i.v. infusion over 10 minutes.
• Figure 3 Mean arterial pressure response to varying doses of JMR-193 administered by i.v. infusion over 10 min.
• Figure 4 Peak coronary flow and mean arterial pressure responses to a bolus injection of JMR-193 (0.3 ⁇ g/kg).
• Figure 5 Pharmacodynamic half-life of a bolus injection of JMR-193 (0.3 ⁇ g/kg).
• FIG. 6 Left circumflex (LCx) coronary flow responses to varying doses of DWH-146e administered by i.v. bolus injection.
• Figure 7 Mean arterial pressure responses to varying doses of DWH -
• Figure 8 Pharmacodynamic half-life of a bolus injection of DWH-146e. Note the plateau phase following bolus administration is of sufficient duration to permit the injection of an imaging tracer.
• Figure 9 Comparison between the coronary flow responses to a 3 min i.v. adenosine infusion versus a bolus injection of DWH-146e in the same dog. Note that the coronary flow response to an i.v. bolus injection of DWH-146e is of greater magnitude and has an equal or greater duration as the standard adenosine infusion.
• Halo is fluoro, chloro, bromo, or iodo.
• Alkyl, alkoxy, aralkyl, alkylaryl, etc. denote both straight and branched alkyl groups; but reference to an individual radical such as "propyl” embraces only the straight chain radical, a branched chain isomer such as "isopropyl” being specifically referred to.
• Aryl includes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic.
• Heteroaryl encompasses a radical attached via a ring carbon of a monocyclic aromatic ring containing five or six ring atoms consisting of carbon and one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(X) wherein X is absent or is H, O, (C,-C 4 )alkyl, phenyl or benzyl, as well as a radical of an ortho-fused bicyclic heterocycle of about eight to ten ring atoms derived therefrom, particularly a benz-derivative or one derived by fusing a propylene, trimethylene, or tetramethylene diradical thereto.
• the compounds of formula (I) have more than one chiral center and may be isolated in optically active and racemic forms.
• the riboside moiety of formula (I) is derived from D-ribose, i.e., the 3 ',4 '-hydroxyl groups are alpha to the sugar ring and the 2' and 5' groups is heia (3R, 4S, 2R, 5S).
• the two groups on the cyclohexyl group are in the 4-position, they are preferably trans. Some compounds may exhibit polymorphism.
• the present invention encompasses any racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, or enzymatic techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine adenosine agonist activity using the tests described herein, or using other similar tests which are well known in the art.
• (C,-C 6 )alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, or hexyl.
• cycloalkyl encompasses (cycloalkyl)alkyl, as well as bicycloalkyl and tricycloalkyl.
• (C 3 -C 6 )cycloalkyl can be cyclopropyl, norbonyl, adamantyl, cyclobutyl, cyclopentyl, or cyclohexyl;
• (C 3 -C 6 )cycloalkyl(C,-C 6 )alkyl can be cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl;, 2- cyclopropylethyl, 2-cyclobutylethyl, 2-cyclopentylethyl, or 2-cyclohexylethyl;
• (C,-C 6 )alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso- butoxy, sec-butoxy, pentoxy, 3-pentoxy, or hexyloxy;
• (C 2 -C 6 )alkenyl can be vinyl, allyl, 1-propeny
• a specific value for R is amino, monomethylamino or cyclopropylamino.
• a specific value for R 1 is carboxy- or (C,-C 4 )alkoxycarbonyl- cyclohexyl(C , -C 4 )alkyl .
• R 2 is H or (C,-C 4 )alkyl, i.e., methyl or ethyl.
• R 3 is H, methyl or phenyl.
• a specific value for R 4 is H, methyl or phenyl.
• a specific value for Z is -CH 2 - or -CH 2 -CH 2 -.
• a specific value for X is CO 2 R 2 , (C 2 -C 5 )alkanoylmethyl or amido.
• n 1
• Preferred compounds of formula (I) are those wherein each R is H, X is ethylaminocarbonyl and R 1 is 4-carboxycyclohexylmethyl (DWH- 146a), R 1 is 4- methoxycarbonylcyclohexylmethyl (DWH-146e) or R 1 is 4-acetoxymethyl- cyclohexylmethyl (JMR-193). They are depicted below (DWH- 146 (acid) and methyl ester (e)) and JMR-193.
• the synthesis of the iodo-adenosine derivative was accomplished from guanosine. Guanosine is first treated with acetic anhydride, which acetalates the sugar hydroxyls, followed by the chlorination of position 6 with tetramethyl ammonium chloride and phosphorousoxychloride. Iodination of position 2 was accomplished via a modified Sandmeyer reaction, followed by displacement of the 6-C1 and sugar acetates with ammonia. The 2' and 3' hydroxyls were protected as the acetonide and the 5' hydroxyl was iodized to the acid with potassium permanganate.
• the cross-coupling reaction was performed under the following previously reported conditions. To a solution of NN-dimethylformamide (0.5 mL), acetonitrile (1 mL), triethylamine (0.25 mL), and N-ethyl-1 '-deoxy-1 '- (amino-2-iodo-9H-purin-9-yl)- ⁇ -D-ribofuranuroamide (25 mg, 0.06 mmol) was added bis(triphenylphosphine)palladium dichloride (1 mg, 2 mol%) and copper(I)iodide (0.06 mg, 0.5 mol%).
• Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, malate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, -ketoglutarate, and -glycerophosphate.
• Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
• Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
• Alkali metal for example, sodium, potassium or lithium
• alkaline earth metal for example calcium
• the compounds of formula I can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or, preferably, parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
• the active compound may also be administered intravenously or intraperitoneally by infusion or injection.
• Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant.
• Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
• the pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes.
• the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
• the proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants.
• the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
• Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile- filtered solutions.
• Useful dosages of the compounds of formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
• the present compounds and compositions containing them are administered as pharmacological stressors and used in conjunction with any one of several noninvasive diagnostic procedures to measure aspects of myocardial perfusion.
• intravenous adenosine may be used in conjunction with thallium-201 myocardial perfusion imaging to assess the severity of myocardial ischemia.
• any one of several different radiopharmaceuticals may be substituted for thallium-201, such as those agents comprising Tc-99m, iodine- 123, nitrogen-13, rubidium-82 and oxygen 13.
• Such agents include technetium 99m labeled radiopharmaceuticals, i.e., technetium 99m-sestamibi, technetium 99m-teboroxime; tetrafosmin and NOET; and iodine 123 labeled radiopharmaceuticals such as I-123-IPPA or BMIPP.
• one of the present compounds may be administered as a pharmacological stressor in conjunction with radionuchde ventriculography to assess the severity of myocardial contractile dysfunction.
• radionuchde ventriculographic studies may be first pass or gated equilibrium studies of the right and/or left ventricle.
• a compound of formula (I) may be administered as a pharmacological stressor in conjunction with echocardiography to assess the presence of regional wall motion abnormalities.
• the active compound may be administered as a pharmacological stressor in conjunction with invasive measurements of coronary blood flow such as by intracardiac catheter to assess the functional significance of stenotic coronary vessels.
• the method typically involves the administration of one or more compounds of formula (I) by intravenous infusion in doses which are effective to provide coronary artery dilation (approximately 0.25-500, preferably 1- 250 mcg/kg/min).
• its use in the invasive setting may involve the intracoronary administration of the drug in bolus doses of 0.5-50 meg.
• Preferred methods comprise the use of a compound of formula (I) as a substitute for exercise in conjunction with myocardial perfusion imaging to detect the presence and/or assess the severity of coronary artery disease in humans wherein myocardial perfusion imaging is performed by any one of several techniques including radiopharmaceutical myocardial perfusion imaging using planar scintigraphy or single photon emission computed tomography (SPECT), positron emission tomograph (PET), nuclear magnetic resonance (NMR) imaging, perfusion contrast echocardiography, digital subtraction angiography (DSA), or ultrafast X-ray computed tomography (CINE CT).
• SPECT single photon emission computed tomography
• PET positron emission tomograph
• NMR nuclear magnetic resonance
• DSA digital subtraction angiography
• CINE CT ultrafast X-ray computed tomography
• a method comprising the use of a compound of formula (I) as a coronary hyperemic agent in conjunction with means for measuring coronary blood flow velocity to assess the vasodilatory capacity (reserve capacity) of coronary arteries in humans wherein coronary blood flow velocity is measured by any one of several techniques including Doppler flow catheter or digital subtraction angiography.
• Example 2 (4-prop-2-ynylcyclohexyl)methan-l-ol (5.3).
• Lithium acetylide ethylenediamine complex (90%) (6.4 g, 70 mmol) was added very slowly to a solution of 5.2 (3 g, 10 mmol) in 40 mL of dimethylsulfoxide.
• the reaction mixture was allowed to stir for 5 days and then slowly quenched at 0°C with water. This mixture was diluted with ether (300 mL) and extracted 3 times with saturated aqueous ammonium chloride (200 mL). The organics were dried with sodium sulfate.
• Example 5 [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(2-amino-6- oxohyropurin-9-yl)oxolan-2-yI] methyl acetate (6.2).
• a suspension of 113 g (0.4 mol) of dry guanosine (6.1), acetic anhydride (240 mL, 2.5 mol), dry pyridine (120 mL) and dry DMF (320 mL) was heated for 3.75 hours at 75°C without allowing the temperature to exceed 80°C. The clear solution was then transferred to a 3L Erlenmyer flask and filled with 2-propanol.
• Example 6 [(2R,3R,4R,5R)-3,4-diacetyIoxy-5-(2-amino-6- chloropurin-9-yl)oxolan-2-yl] methyl acetate (6.3). To a 1000 mL flask was added 80 g (0.195 mol) [(2R,3R,4R,5R)-3-4-diacetyloxy-5-(2-amino-6- oxohyropurin-9-yl)oxolan-2-yl]methyl acetate (6.2), tetramethylammonium chloride (44 g, 0.4 mol), anhydrous acetonitrile (400 mL) and N,N- dimethlaniline (25 mL).
• the flask was placed in an ice salt bath and cooled to 2°C. To this solution was added dropwise POCl 3 (107 mL 1.15 mol) at a rate that maintained the temperature below 5°C (45 minutes). The flask was then removed from the ice bath, outfitted with a condenser, placed in an oil bath and allowed to reflux for 10 minutes whereas the solution changed to a red/brown color. The solvent was then removed under reduced pressure to yield an oily residue which was transferred to a beaker containing 1000 g of ice and 400 mL of CHC1 3 and allowed to stir for 1.5 hours to decompose any remaining POCl 3 .
• the organic phase was then removed and the aqueous phase extracted with 3 * 50 mL of CHC1 3 and pooled with the organic phase.
• the pooled organic was then back extracted with 50 mL of water followed by stirring with 200 mL of saturated NaHCO 3 .
• the organic was further extracted with NaHCO 3 until the aqueous extract was neutral (2X).
• the organic was finally extracted with brine and then dried over MgSO 4 for 16 hours.
• To the solution was added 800 mL of 2-propanol after which the solution was concentrated under reduced pressure.
• To the oily solid was added 200 mL of 2-propanol and the solution was refrigerated overnight. The crystalline product was filtered, washed, and allowed to dry overnight to give 6.3 (77%).
• Isoamyl nitrite (5 mL, 37 mmol) was added to a mixture of 5.12 g (12 mmol) [(2R,3R,4R,5R)-3-,4-diacetyloxy-5-(2- amino-6-chloropurin-9-yl)oxolan-2-yl]methyl acetate (6.3), I 2 (3.04 g, 12 mmol), CH 2 I 2 (10 mL, 124 mmol), and Cul (2.4 g, 12.6 mmol) in THF (60 mL). The mixture was heated under reflux for 45 minutes and then allowed to cool to room temperature. To this solution was added 100 ml of sat.
• Example 8 (4S,2R,3R,5R)-2-(6-amino-2-iodopurin-9-yl)-5- (hydroxymethyl)oxolane-3,4-diol (6.5).
• Example 9 [(lR,2R,4R,5R)-4-(6-amino-2-iodopurin-9-yl)-7-7- dimethyl-3,6,8-trioxabicyclo[3.3.0]oct-2-yl]methan-l-ol (6.6).
• the reaction mixture was then cooled to 5-10°C and decolorized by a solution of 4 mL of 30% H 2 O 2 in 16 mL of water, while the temperature was maintained under 10°C using an ice-salt bath.
• the mixture was filtered through Celite and the filtrate was concentrated under reduced pressure to about 10 mL and then acidified to pH 4 with 2N HC1.
• the resulting precipitate was filtered off and washed with ether to yield 6.7 (70%) after drying as a white solid, m.p. 187-190°C.
• (2S,3S,4R,5R)-5-(6-amino-2-iodopurin-9-yl)-3,4- dihydroxyoxolane-2-carboxylic acid (6.8).
• a solution of 1.72 g (3.85 mmol) of (2S,lR,4R,5R)-4-(6-amino-2-iodopurin-9-yl)-7,7-dimethyl-3,6,8- trioxabicyclo[3.3.0]octane-2-carboxylic acid (6.7) in 80 mL of 50% HCOOH was stirred at 80°C for 1.5 hours.
• the reaction mixture was evaporated under reduced pressure, dissolved in H 2 O, and the solution was evaporated again.
• Example 12 [(2S,3S,4R,5R)-5-(6-amino-2-iodopurin-9-yl)-3,4- dihydroxyoxolan-2-yl]-N-ethylcarboxamide (6.9).
• the mixture was stirred at room temperature overnight and then brought to pH 8 with saturated aqueous NaHCO 3 .
• the mixture was filtered, and then the filtrate was concentrated under reduced pressure to yield a white solid which was dried and then redissolved in 20 mL of dry ethylamine at -20°C for 3 hours and then at room temperature overnight.
• the reaction mixture was diluted with absolute ethanol, and the precipitated product was filtered off and washed with dry ether to give 530 mg (72%) of 6.9 as a pure solid, m.p. 232-234°C.
• Example 14 (4-prop-2-ynylcyclohexyl)methyl acetate (5.6). Acetic anhydride (0.92 mL, 8.25 mmol) and pyridine (.2 mL, 2.5 mmol) were added to a solution of 5.3 (250 mg, 1.65 mmol) in 25 mL ether. The reaction was allowed to stir at ambient temperature for 24 h. Water was added to the reaction and the organic was further extracted with 10% NaHCO 3 . The organic layer was dried with MgSO 4 and evaporated. The residue was chromatographed on silica gel with EtOAc-Hexanes (5:95) to yield 5.6 (47%). Example 15.
• Example 16 Radioligand Binding Studies. Binding to A 2A receptors was evaluated with the radioligand 125 I-ZM241385.
• Figure 1 depicts the competition by selective agonists for binding to recombinant human A 2A adenosine receptors.
• DWH-146e is highly selective for the recombinant human A 2A (hA2A) subtype. Selectivity for the A 3 receptor (not shown) is less impressive, but still about 50-fold.
• DWH-146e is about 5 and 50 times more potent than WRC0470 and CGS21680, respectively (Fig. 1).
• An unexpected and interesting finding is that the ester, DWH-146e also is about 50 times more potent than the acid, DWH-146a (Fig. 1).
• a thoracotomy was performed at the level of the fifth intercostal space and the heart suspended in a pericardial cradle.
• a cut-down was performed on the left side of the neck, and a Millar pressure catheter advanced through the carotid artery until its tip rested inside the left ventricle.
• the first derivative of LV pressure (dP/dt) was obtained by electronic differentiation.
• a flared polyethylene tube was placed in the left atrial appendage for pressure measurement and for injection of microspheres.
• a snare ligature was loosely placed on a proximal portion of the left anterior descending coronary artery (LAD).
• Ultrasonic flow probes (T206, Transonic Systems, Inc.) were placed on a more distal portion of the LAD and on the left circumflex coronary artery (LCX). For both protocols, ECG lead II, arterial and left atrial pressures, LAD and LCX flows, and LV pressure and its first derivative were continuously monitored and recorded on a 16-channel thermal array stripchart recorder (model K2G, Astromed, Inc.). In addition to the analog recording, all of the physiologic signals were digitized and stored on an optical disk for subsequent analysis and archival purposes.
• JMR-193 increased LCX coronary flow in a dose-dependent manner from 42 ml/min at baseline to 66, 75, 124, 153, and 140 ml/min at 0.05, 0.1, 0.2, 0.3, and 0.4 ⁇ g kg/min x 10 min, respectively.
• JMR-193 With bolus administration (0.3 ⁇ g/kg), JMR-193 increased LCX flow from 41 to 140 ml/min with a minimal decrease in arterial pressure (111 to 100 mm Hg) (Fig. 4). Maximal LCX flow occurred 2.3 min post-injection and flow remained elevated more than 2X normal for 3-4 min (Fig. 4). This extended flow response following bolus administration should make JMR-193 well-suited for clinical imaging protocols. In conclusion, these data show that JMR-193 is useful as a pharmacologic stressor with myocardial perfusion imaging.
• Example 18 Use of DWH-146e in Pharmacologic Stress Perfusion Imaging.
• the canine surgical preparation of Example 15 was employed. Following a 15 minute baseline stabilization period, the LAD snare occluder was tightened to produce a critical LAD stenosis.
• a critical stenosis was defined as one that produced no change in resting coronary flow, however coronary flow reserve was completely abolished.
• an i.v. infusion of DWH-146e (0.3 ⁇ g/kg/min) was begun and continued for 5 minutes at which time LCX coronary flow was maximal.
• DWH-146e infusion increased coronary flow nearly 5- fold in the normal LCX coronary artery.
• coronary flow in the LAD coronary artery remained constant due to the presence of the flow-limiting coronary stenosis.
• the in vivo and ex vivo images from this dog showed readily detectable large anteroseptal perfusion defects.
• the 99m Tc-N-NOET defect count ratio was identical on both the in vivo and ex vivo images and was similar to what is observed using adenosine and 201 Thallium imaging in dogs with the same degree of coronary stenosis.
• Example 19 Use of an i.v. bolus of DWH-146e in Pharmacologic Stress Perfusion Imaging.
• the canine surgical preparation of Example 15 was employed. Following a 15 minute baseline stabilization period, the LAD snare occluder was tightened to produce a critical LAD stenosis.
• a critical stenosis was defined as one that produced no change in resting coronary flow, however coronary flow reserve was completely abolished.
• the heart was removed and sliced into 4 rings from apex to base.
• the heart slices were placed on a cardboard sheet, covered with plastic wrap, and ex vivo imaging of the heart slices was performed directly on the collimator of a conventional planar gamma camera.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Molecular Biology (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Physics & Mathematics (AREA)
• General Chemical & Material Sciences (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Genetics & Genomics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Optics & Photonics (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Saccharide Compounds (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Priority Applications (14)

Applications Claiming Priority (2)

Publications (2)

Family

ID=23314994

Family Applications (1)

Country Status (22)

Cited By (52)

Families Citing this family (51)

Family Cites Families (39)

• 1999
  • 1999-06-18 US US09/336,198 patent/US6322771B1/en not_active Expired - Lifetime
• 2000
  • 2000-06-12 JP JP2001504939A patent/JP4890705B2/ja not_active Expired - Fee Related
  • 2000-06-12 KR KR1020017016107A patent/KR100683607B1/ko not_active Expired - Fee Related
  • 2000-06-12 DK DK00941335T patent/DK1194440T3/da active
  • 2000-06-12 PT PT00941335T patent/PT1194440E/pt unknown
  • 2000-06-12 WO PCT/US2000/016029 patent/WO2000078774A2/en not_active Ceased
  • 2000-06-12 NZ NZ516169A patent/NZ516169A/xx not_active IP Right Cessation
  • 2000-06-12 BR BR0011725-0A patent/BR0011725A/pt not_active Application Discontinuation
  • 2000-06-12 MX MXPA01013213A patent/MXPA01013213A/es active IP Right Grant
  • 2000-06-12 AT AT00941335T patent/ATE289317T1/de not_active IP Right Cessation
  • 2000-06-12 CA CA2375374A patent/CA2375374C/en not_active Expired - Fee Related
  • 2000-06-12 AU AU56051/00A patent/AU5605100A/en not_active Abandoned
  • 2000-06-12 EP EP00941335A patent/EP1194440B1/en not_active Expired - Lifetime
  • 2000-06-12 HU HU0202094A patent/HU229005B1/hu not_active IP Right Cessation
  • 2000-06-12 DE DE60018185T patent/DE60018185T2/de not_active Expired - Lifetime
  • 2000-06-12 IL IL14693900A patent/IL146939A0/xx active IP Right Grant
  • 2000-06-12 ES ES00941335T patent/ES2233401T3/es not_active Expired - Lifetime
  • 2000-06-14 TW TW089111546A patent/TW585870B/zh not_active IP Right Cessation
  • 2000-06-16 AR ARP000103042A patent/AR030151A1/es not_active Application Discontinuation
  • 2000-06-16 MY MYPI20002713 patent/MY126794A/en unknown
• 2001
  • 2001-12-05 IL IL146939A patent/IL146939A/en not_active IP Right Cessation
  • 2001-12-06 NO NO20015974A patent/NO322229B1/no not_active IP Right Cessation
• 2002
  • 2002-01-15 ZA ZA200200342A patent/ZA200200342B/en unknown

Also Published As

Similar Documents

Legal Events